Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

被引：0
|
作者：
Jasmeet Chadha Singh
Yelena Novik
Stacey Stein
Matthew Volm
Marlene Meyers
Julia Smith
Coral Omene
James Speyer
Robert Schneider
Komal Jhaveri
Silvia Formenti
Victoria Kyriakou
Benson Joseph
Judith D Goldberg
Xiaochun Li
Sylvia Adams
Amy Tiersten
机构：
[1] New York University Medical Center,Department of Medicine, Division of Hematology
[2] New York University Cancer institute,Oncology
[3] Yale Medical Center,Department of Medicine, Division of Hematology
[4] New York University Medical Center,Oncology
[5] NYU Cancer Institute,Department of Radiation Oncology
[6] New York University School of Medicine,Clinical trials office
[7] Mt Sinai School of Medicine,Division of Biostatistics
[8] Mt Sinai School of Medicine,Department of Medicine, Division of Hematology
来源：
Breast Cancer Research | / 16卷
关键词：
Trastuzumab; Carboplatin; Cetuximab; International Normalize Ratio; Everolimus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
    Singh, Jasmeet Chadha
    Novik, Yelena
    Stein, Stacey
    Volm, Matthew
    Meyers, Marlene
    Smith, Julia
    Omene, Coral
    Speyer, James
    Schneider, Robert
    Jhaveri, Komal
    Formenti, Silvia
    Kyriakou, Victoria
    Joseph, Benson
    Goldberg, Judith D.
    Li, Xiaochun
    Adams, Sylvia
    Tiersten, Amy
    BREAST CANCER RESEARCH, 2014, 16 (02):
  • [2] A Phase 2 trial of RAD 001 and Carboplatin in patients with triple negative metastatic breast cancer
    Singh, J. C.
    Volm, M.
    Novik, Y.
    Speyer, J.
    Adams, S.
    Omene, C. O.
    Meyers, M.
    Smith, J. A.
    Schneider, R.
    Formenti, S.
    Goldberg, J. D.
    Li, X.
    Davis, S.
    Beardslee, B.
    Tiersten, A.
    CANCER RESEARCH, 2012, 72
  • [3] Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
    Lee, Jin Sun
    Yost, Susan E.
    Blanchard, Suzette
    Schmolze, Daniel
    Yin, Hongwei Holly
    Pillai, Raju
    Robinson, Kim
    Tang, Aileen
    Martinez, Norma
    Portnow, Jana
    Wen, Wei
    Yim, John H.
    Brauer, Heather Ann
    Ren, Yuqi
    Luu, Thehang
    Mortimer, Joanne
    Yuan, Yuan
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [4] Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
    Jin Sun Lee
    Susan E. Yost
    Suzette Blanchard
    Daniel Schmolze
    Hongwei Holly Yin
    Raju Pillai
    Kim Robinson
    Aileen Tang
    Norma Martinez
    Jana Portnow
    Wei Wen
    John H. Yim
    Heather Ann Brauer
    Yuqi Ren
    Thehang Luu
    Joanne Mortimer
    Yuan Yuan
    Breast Cancer Research, 21
  • [5] Phase I trial of eribulin and everolimus in patients with metastatic triple negative breast cancer
    Yuan, Y.
    Yost, S.
    Blanchard, S.
    Yin, H.
    Li, M.
    Robinson, K.
    Tang, A.
    Martinez, N.
    Leong, L.
    Somlo, G.
    Patel, N. Tank
    Waisman, J.
    Portnow, J.
    Hurria, A.
    Luu, T-H
    Mortimer, J.
    CANCER RESEARCH, 2019, 79 (04)
  • [6] The mTOR Inhibitor Everolimus in Combination with Carboplatin in Metastatic Breast Cancer - a Phase I Trial
    Schwarzlose-Schwarck, Sandra
    Scholz, Christian W.
    Regierer, Anne C.
    Martus, Peter
    Neumann, Christian
    Habbel, Piet
    Liu, Hongyu
    Zang, Chuanbing
    Schefe, Jan-Hendrik
    Schulz, Carsten-Oliver
    Possinger, Kurt
    Eucker, Jan
    ANTICANCER RESEARCH, 2012, 32 (08) : 3435 - 3441
  • [7] A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer
    Cowherd, S.
    Miller, L. D.
    Melin, S. A.
    Akman, S.
    Isom, S.
    Cole, J.
    Pullikuth, A.
    Lawrence, J. A.
    CANCER BIOLOGY & THERAPY, 2015, 16 (05) : 678 - 683
  • [8] A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease
    Cowherd, Stacy
    Melin, Susan
    Akman, Steven
    Cole, John
    Lawrence, Julia
    CANCER RESEARCH, 2014, 74 (19)
  • [9] RAD001-carboplatin combination in triple-negative metastatic breast cancer (TNMBC): A phase II trial
    Singh, Jasmeet Chadha
    Stein, Stacy
    Volm, Matthew
    Smith, Julia Anne
    Adams, Sylvia
    Meyers, Marlene
    Speyer, James L.
    Novik, Yelena
    Schneider, Robert
    Formenti, Sylvia
    Muggia, Franco
    Jhaveri, Komal L.
    Goldberg, Judith D.
    Heese, Scott
    Li, Xiaochun
    Davis, Samantha
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer The TBCRC 043 Phase 2 Randomized Clinical Trial
    Lehmann, Brian D.
    Abramson, Vandana G.
    Dees, E. Claire
    Shah, Payal D.
    Ballinger, Tarah J.
    Isaacs, Claudine
    Santa-Maria, Cesar A.
    An, Hanbing
    Gonzalez-Ericsson, Paula I.
    Sanders, Melinda E.
    Newsom, Kimberly C.
    Abramson, Richard G.
    Sheng, Quanhu
    Hsu, Chih-Yuan
    Shyr, Yu
    Wolff, Antonio C.
    Pietenpol, Jennifer A.
    JAMA ONCOLOGY, 2024, 10 (02) : 193 - 201
12345